k Estimate is derived from rate of systemic embolism on aspirin per patient-y) reported in the IPD meta-analysis by van Walraven et al and estimated relative risk of CI, for systemic embolism with combination aspirin clopidogrel therapy vs aspirin observed in ACTIVE A ( Table ). e548S Antithrombotic Therapy for Atrial Fibrillation results of a three-arm RCT of 18,113 patients with AF in which dabigatran 110 mg bid, and dabiga- tran 150 mg bid, were compared with open-label, adjusted-dose warfarin (target INR 2.0-3.0).84 Based on best estimates of the proportion of strokes and major extracranial bleeds that were nonfatal (the published report did not present the number or proportion of fatal and nonfatal events), dabigatran at a dose of 150 mg bid is associated with a statisti- cally signi cant one-third reduction in nonfatal stroke, with no evidence of a difference in the risk of nonfa- tal major extracranial bleeding compared with war- farin. Moreover, the data raised the possibility that dabigatran 150 mg bid may reduce all-cause mortality compared with warfarin (relative risk, 0.89; 95% CI, 0.79-1.01) (Table 9). In contrast, dabigatran at a dose of 110 mg bid was not associated with a signi cant difference in the risk of death, nonfatal stroke, nonfa- tal major extracranial bleeding, or systemic embolism (Table 10). 